65,437 trials
Attention Deficit Disorder With Hyperactivity
Primary: Sustained Effects in Attention From End-of-treatment (Follow-Up Day 0) to Follow-Up Day 28 Within Groups That Were Previously Randomized to Receive 4 Weeks of Digital…
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Methamphetamine · Alcohol
Primary: Feasibility of Retaining Participants in Trial — 100; 86.7 percentage that completed study
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
Surgical Site Infection · Pancreatic Neoplasms · Pancreatic Cancer
Primary: Rate of Surgical Site Infection — 6; 19 Participants — p=0.003
Venous Stasis · Deep Vein Thrombosis
Primary: Blood Flow - Peak Systolic Velocity (cm/Sec) — 14.1; 29.5; 161.6; 39.0 cm/s
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) — 6.8…
Leiomyoma · Uterine Fibroids
Primary: Changes in Fibroid-related Symptoms After Treatment With Letrozole — -10.42; 1.43 units on a scale — p=0.24
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Malignant Melanoma
Primary: Clinical Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide — 17; 4; 0; 1 Participants
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
Primary Sjögren's Syndrome
Primary: Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 11.1; 14.5; 11.5; 12.5 units on a scale — p=0.678
Dental Caries
Primary: Number of Lesions With Progression as Measured by Pairwise (PW) Comparison (N=Lesions) — 4; 14 Lesions — p==0.003
Influenza A Virus, H5N1 Subtype
Primary: Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A…